Updates in the management of inflammatory bowel disease during pregnancy

Sally J Bell and Emma K Flanagan
Med J Aust 2019; 210 (6): . || doi: 10.5694/mja2.50062
Published online: 25 March 2019



  • The best pregnancy outcomes for women with inflammatory bowel disease (IBD) occur when their disease is in remission at conception and remains in remission throughout pregnancy.
  • Active IBD can lead to adverse pregnancy outcomes, including spontaneous abortion, pre‐term birth and low birthweight.
  • The majority of women with IBD who are taking maintenance medication will require medication throughout the pregnancy to prevent disease relapse.
  • Most IBD medications are considered safe in pregnancy and breastfeeding, except for methotrexate.
  • Pre‐conception counselling should be arranged with the patient's IBD specialist and should include discussions regarding the importance of optimising disease control before and during pregnancy as well as the medication management plan for pregnancy.
  • Patients with IBD should be reassured that their fertility is normal when the disease is quiescent, with the exception of women who have had pelvic surgery.
  • IBD activity should be carefully monitored during pregnancy using non‐invasive techniques, and disease flares during pregnancy should be treated promptly with escalation of therapy in consultation with the patient's IBD specialist.
  • Mode of delivery should be determined by obstetric need; however, caesarean delivery is preferred for women with a history of ileal pouch anal anastomosis surgery or active perianal Crohn's disease.


  • St Vincent's Hospital, Melbourne, VIC


Competing interests:

No relevant disclosures.

  • 1. Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology 2017; 152: 451–462.
  • 2. Nielsen MJ, Nørgaard M, Holland‐Fisher P, Christensen LA. Self‐reported antenatal adherence to medical treatment among pregnant women with Crohn's disease. Alimentary Pharmacol Ther 2010; 32: 49–58.
  • 3. Julsgaard M, Nørgaard M, Hvas CL, et al. Self‐reported adherence to medical treatment before and during pregnancy among women with ulcerative colitis. Inflamm Bowel Dis 2011; 17: 1573–1580.
  • 4. Selinger C, Eaden J, Selby W, et al. Patients’ knowledge of pregnancy‐related issues in inflammatory bowel disease and validation of a novel assessment tool (“CCPKnow”). Aliment Pharmacol Ther 2012; 36: 57–63.
  • 5. Kashkooli SB, Andrews JM, Roberts MB, et al. Inflammatory bowel disease‐specific pregnancy knowledge of gastroenterologists against general practitioners and obstetricians. United European Gastroenterol J 2015; 3: 462–470.
  • 6. Wright EK, Ding NS, Niewiadomski O. Management of inflammatory bowel disease. Med J Aust 2018; 209: 318–323.
  • 7. Nguyen GC, Seow CH, Maxwell C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 2016; 150: 734–757.
  • 8. van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced‐based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 2015; 9: 107–124.
  • 9. Selinger CP, Eaden J, Selby W, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis 2013; 7: e206–e213.
  • 10. Mountifield R, Bampton P, Prosser R, et al. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis 2008; 15: 720–725.
  • 11. Hudson M, Flett G, Sinclair T, et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 1997; 58: 229–237.
  • 12. Olsen KØ, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002; 122: 15–19.
  • 13. Tavernier N, Fumery M, Peyrin‐Biroulet L, et al. Systematic review: fertility in non‐surgically treated inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 847–853.
  • 14. Levi A, Fisher A, Hughes L, Hendry W. Male infertility due to sulphasalazine. Lancet 1979; 314: 276–278.
  • 15. Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol 1980; 116: 215–217.
  • 16. Waljee A, Waljee J, Morris A, Higgins PD. Threefold increased risk of infertility: a meta‐analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006; 55: 1575–1580.
  • 17. Oresland T, Palmblad S, Ellstrom M, et al. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int J Colorect Dis 1994; 9: 77–81.
  • 18. Bartels SA, D'Hoore A, Cuesta MA, et al. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross‐sectional study. Ann Surg 2012; 256: 1045–1048.
  • 19. Beyer‐Berjot L, Maggiori L, Birnbaum D, et al. A total laparoscopic approach reduces the infertility rate after ileal pouch‐anal anastomosis: a 2‐center study. Ann Surg 2013; 258: 275–282.
  • 20. Pabby V, Oza SS, Dodge LE, et al. In vitro fertilization is successful in women with ulcerative colitis and ileal pouch anal anastomosis. Am J Gastroenterol 2015; 110: 792.
  • 21. Cornish J, Tan E, Teare J, et al. A meta‐analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56: 830–837.
  • 22. Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community‐based study from Northern California. Gastroenterology 2007; 133: 1106–1112.
  • 23. Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis 2010; 17: 795–801.
  • 24. Bröms G, Granath F, Linder M, et al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis 2014; 20: 1091–1098.
  • 25. Abhyankar A, Ham M, Moss AC. Meta‐analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 460–466.
  • 26. Pedersen N, Bortoli A, Duricova D, et al. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO‐EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther 2013; 38: 501–512.
  • 27. de Lima A, Zelinkova Z, Mulders AG, van der Woude CJ. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol 2016; 14: 1285–1292.e1.
  • 28. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Vitamin and mineral supplementation and pregnancy. RANZCOG, 2015.,-Amended-May-2015.pdf?ext=.pdf (viewed July 2018).
  • 29. Orholm M, Fonager K, Sørensen HT. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3236.
  • 30. Laharie D, Debeugny S, Peeters M, et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001; 120: 816–819.
  • 31. Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 1991; 100: 1638–1643.
  • 32. Klajnbard A, Szecsi PB, Colov NP, et al. Laboratory reference intervals during pregnancy, delivery and the early postpartum period. Clin Chem Lab Med 2010; 48: 237–248.
  • 33. Julsgaard M, Hvas CL, Gearry RB, et al. Fecal calprotectin is not affected by pregnancy. Inflamm Bowel Dis 2017; 23: 1240–1246.
  • 34. Tremblay E, Thérasse E, Thomassin‐Naggara I, Trop I. Quality initiatives: guidelines for use of medical imaging during pregnancy and lactation. Radiographics 2012; 32: 897–911.
  • 35. de Lima A, Zelinkova Z, van der Woude CJ. A prospective study of the safety of lower gastrointestinal endoscopy during pregnancy in patients with inflammatory bowel disease. J Crohns Colitis 2015; 9: 519–524.
  • 36. Magro F, Gionchetti P, Eliakim R, et al. Third European evidence‐based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra‐intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo‐anal pouch disorders. J Crohns Colitis 2017; 11: 649–670.
  • 37. Gomollon F, Dignass A, Annese V, et al. 3rd European evidence‐based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis 2017; 11: 3–25.
  • 38. Abeywardana S, Sullivan EA. Congenital anomalies in Australia 2002–2003 (AIHW Cat. No. PER 41, Birth Anomalies Series No. 3). Sydney: Australian Institute of Health and Welfare, 2008. (viewed July 2018).
  • 39. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5‐aminosalicylic acid drugs: a meta‐analysis. Reprod Toxicol 2008; 25: 271–275.
  • 40. Park‐Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta‐analysis of epidemiological studies. Teratology 2000; 62: 385–392.
  • 41. Hviid A, Mølgaard‐Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. Can Med Ass J 2011; 183: 796–804.
  • 42. Lin K, Martin CF, Dassopoulos T, et al. Pregnancy outcomes among mothers with inflammatory bowel disease exposed to systemic corticosteroids: results of the PIANO Registry (abstract). Gastroenterology 2014; 146: S–1.
  • 43. Hutson J, Matlow J, Moretti M, Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol 2013; 33: 1–8.
  • 44. Casanova M, Chaparro M, Domenech E, et al. Safety of thiopurines and anti‐TNF‐α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 433.
  • 45. Mahadevan U, Martin CF, Sandler RS, et al. 865 PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy (abstract). Gastroenterology 2012; 142: S–149.
  • 46. Kanis SL, de Lima‐Karagiannis A, de Boer NK, van der Woude CJ. Use of thiopurines during conception and pregnancy is not associated with adverse pregnancy outcomes or health of infants at one year in a prospective study. Clin Gastroenterol Hepatol 2017; 15: 1232–1241.
  • 47. Narula N, Al‐Dabbagh R, Dhillon A, et al. Anti‐TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta‐analysis. Inflamm Bowel Dis 2014; 20: 1862–1869.
  • 48. Shihab Z, Yeomans ND, De Cruz P. Anti‐tumour necrosis factor alpha therapies and inflammatory bowel disease pregnancy outcomes: a meta‐analysis. J Crohns Colitis 2016; 10: 979–988.
  • 49. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti‐tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286–292.
  • 50. Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology 2016; 151: 110–119.
  • 51. Nielsen OH, Loftus EV, Jess T. Safety of TNF‐alpha inhibitors during IBD pregnancy: a systematic review. BMC Med 2013; 11: 174.
  • 52. Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther 2017; 45: 941–950.
  • 53. Deepak P, Sandborn WJ. Ustekinumab and anti‐interleukin‐23 agents in Crohn's disease. Gastroenterol Clin North Am 2017; 46: 603–626.
  • 54. Foulon A, Dupas JL, Sabbagh C, et al. Defining the most appropriate delivery mode in women with inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2017; 23: 712–720.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.